Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $4.5 million.

  • Tg Therapeutics' Gains from Investment Securities was N/A to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $4.5 million for FY2024, which is 4.83% down from last year.
  • Tg Therapeutics' Gains from Investment Securities amounted to $4.5 million in FY2024, which was down 4.83% from $4.7 million recorded in FY2023.
  • Tg Therapeutics' Gains from Investment Securities' 5-year high stood at $5.1 million during FY2022, with a 5-year trough of $2.5 million in FY2021.
  • For the 3-year period, Tg Therapeutics' Gains from Investment Securities averaged around $4.8 million, with its median value being $4.7 million (2023).
  • As far as peak fluctuations go, Tg Therapeutics' Gains from Investment Securities soared by 108.13% in 2022, and later dropped by 8.54% in 2023.
  • Tg Therapeutics' Gains from Investment Securities (Yearly) stood at $2.5 million in 2020, then declined by 2.32% to $2.5 million in 2021, then spiked by 108.13% to $5.1 million in 2022, then dropped by 8.54% to $4.7 million in 2023, then fell by 4.83% to $4.5 million in 2024.